Study of Escitalopram in the Treatment of Specific Phobia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2004-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Phobic Disorders

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

specific phobia anxiety SSRI clinical trial escitalopram

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults 18-65 years of age
* DSM-IV criteria for specific phobia according to the MINI
* For women of childbearing potential, a negative serum pregnancy test at screening
* Written informed consent

Exclusion Criteria

* Any current primary DSM-IV diagnosis other than specific phobia
* History of DSM-IV substance abuse or dependence within the last months
* Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
* Suicide risk or serious suicide attempt within the last year
* Clinically significant laboratory or EKG abnormality or unstable medical condition
* For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
* Subjects needing concurrent use of psychotropic medications

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kathryn M. Connor, M.D.

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center

Durham, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3990-02-9

Identifier Type: -

Identifier Source: org_study_id